

Sihuan Pharma acquires antibody technology firm Combio

28 January 2021 | News

The acquisition has fully expanded the depth and breadth of the company's innovative drug product pipeline



Sihuan Pharmaceutical Holdings Group Ltd. has announced that its innovation Xuanzhu Biopharmaceutical Co., Ltd., a pharmaceutical platform company, will acquire 100% of the shares of Beijing Combio Pharmaceutical.

The acquisition of Combio Pharmaceutical by Xuanzhu Biopharm has fully expanded the depth and breadth of the company's innovative drug product pipeline, and introduced the highly potential "Mab Edit" (antibody editing) and "Mabs-Ig" (antibody editing bispecific antibodies), two major antibody technology platforms.

Xuanzhu Biopharm has a total of 14 innovative product projects under research, and the pipeline covers multiple fields such as oncology, metabolic disorders and infectious diseases, many of which have entered the late clinical stage.

The leading product Birociclib has successfully carried out clinical trials on 3 indications and is a CDK4/6 inhibitor for advanced breast cancer. Among them, the single-drug treatment of Birociclib is already in phase II clinical trials, and if relevant requirements are met, phase III clinical trials can be skipped directly for marketing.

On the other hand, Combio Pharmaceutical product pipeline already has 12 products under development, of which KM257/252 is a bispecific antibody drug for cholangiocarcinoma, breast cancer, gastroesophageal cancer, etc.